Literature DB >> 19515760

A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle.

Sook-Kyung Lee1, Janera Harris, Ronald Swanstrom.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) protease (PR) makes five obligatory cleavages in the viral Gag polyprotein precursor. The cleavage events release the virion structural proteins from the precursor and allow the virion to undergo maturation to become infectious. The protease cleavage between the matrix protein (MA) domain and the adjacent capsid protein (CA) domain releases CA from the membrane-anchored MA and allows the N terminus of CA to refold into a structure that facilitates the formation of hexamer arrays that represent the structural unit of the capsid shell. In this study, we analyzed the extent to which each of the HIV-1 Gag processing sites must be cleaved by substituting the P1-position amino acid at each processing site with Ile. A mutation that blocks cleavage at the MA/CA processing site (Y132I) displayed a strong transdominant effect when tested in a phenotypic mixing strategy, inhibiting virion infectivity with a 50% inhibitory concentration of only 4% of the mutant relative to the wild type. This mutation is 10- to 20-fold more potent in phenotypic mixing than an inactivating mutation in the viral protease, the target of many successful inhibitors, and more potent than an inactivating mutation at any of the other Gag cleavage sites. The transdominant effect is manifested as the assembly of an aberrant virion core. Virus containing 20% of the Y132I mutant and 80% of the wild type (to assess the transdominant effect on infectivity) was blocked either before reverse transcription (RT) or at an early RT step. The ability of a small amount of the MA/CA fusion protein to poison the oligomeric assembly of infectious virus identifies an essential step in the complex process of virion formation and maturation. The effect of a small-molecule inhibitor that is able to block MA/CA cleavage even partially would be amplified by this transdominant negative effect on the highly orchestrated process of virion assembly.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515760      PMCID: PMC2738153          DOI: 10.1128/JVI.00317-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses.

Authors:  Scott Crowder; Karla Kirkegaard
Journal:  Nat Genet       Date:  2005-06-19       Impact factor: 38.330

2.  The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor.

Authors:  François Ternois; Jana Sticht; Stéphane Duquerroy; Hans-Georg Kräusslich; Félix A Rey
Journal:  Nat Struct Mol Biol       Date:  2005-07-24       Impact factor: 15.369

3.  Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag.

Authors:  S J Rulli; D Muriaux; K Nagashima; J Mirro; M Oshima; J G Baumann; A Rein
Journal:  Virology       Date:  2006-01-19       Impact factor: 3.616

4.  Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278).

Authors:  Brian N Kelly; Bruce R Howard; Hui Wang; Howard Robinson; Wesley I Sundquist; Christopher P Hill
Journal:  Biochemistry       Date:  2006-09-26       Impact factor: 3.162

5.  Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles.

Authors:  Jing Zhou; Li Huang; David L Hachey; Chin Ho Chen; Christopher Aiken
Journal:  J Biol Chem       Date:  2005-10-25       Impact factor: 5.157

6.  Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag.

Authors:  Jing Zhou; Chin Ho Chen; Christopher Aiken
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication.

Authors:  Ingrid Bahner; Teiko Sumiyoshi; Mercy Kagoda; Robin Swartout; Denise Peterson; Karen Pepper; Fred Dorey; Jacob Reiser; Donald B Kohn
Journal:  Mol Ther       Date:  2007-01       Impact factor: 11.454

8.  Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein.

Authors:  Brian N Kelly; Sampson Kyere; Isaac Kinde; Chun Tang; Bruce R Howard; Howard Robinson; Wesley I Sundquist; Michael F Summers; Christopher P Hill
Journal:  J Mol Biol       Date:  2007-08-15       Impact factor: 5.469

9.  Dominant negative inhibition of human immunodeficiency virus particle production by the nonmyristoylated form of gag.

Authors:  Shigeo Kawada; Toshiyuki Goto; Hiyori Haraguchi; Akira Ono; Yuko Morikawa
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

10.  Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1.

Authors:  Lori V Coren; James A Thomas; Elena Chertova; Raymond C Sowder; Tracy D Gagliardi; Robert J Gorelick; David E Ott
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

View more
  57 in total

1.  Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.

Authors:  Chris M Parry; Madhavi Kolli; Richard E Myers; Patricia A Cane; Celia Schiffer; Deenan Pillay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

2.  BST-2 diminishes HIV-1 infectivity.

Authors:  Jianyong Zhang; Chen Liang
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

3.  The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Ferri Soheilian; Kunio Nagashima; Eric O Freed
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

Review 4.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

5.  RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly.

Authors:  Simone Mattei; Annica Flemming; Maria Anders-Össwein; Hans-Georg Kräusslich; John A G Briggs; Barbara Müller
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 6.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

7.  Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Authors:  Wei Wang; Nada Naiyer; Mithun Mitra; Jialin Li; Mark C Williams; Ioulia Rouzina; Robert J Gorelick; Zhengrong Wu; Karin Musier-Forsyth
Journal:  Nucleic Acids Res       Date:  2014-05-09       Impact factor: 16.971

8.  The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15.

Authors:  Larissa A Durfee; Nancy Lyon; Kyungwoon Seo; Jon M Huibregtse
Journal:  Mol Cell       Date:  2010-06-11       Impact factor: 17.970

9.  Structural analysis of HIV-1 maturation using cryo-electron tomography.

Authors:  Alex de Marco; Barbara Müller; Bärbel Glass; James D Riches; Hans-Georg Kräusslich; John A G Briggs
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

10.  Cryo electron tomography of native HIV-1 budding sites.

Authors:  Lars-Anders Carlson; Alex de Marco; Heike Oberwinkler; Anja Habermann; John A G Briggs; Hans-Georg Kräusslich; Kay Grünewald
Journal:  PLoS Pathog       Date:  2010-11-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.